Swiss Parliament Approves Mandatory Electronic Prescriptions.

Switzerland is taking a major step toward digitalising its healthcare system after the Swiss parliament approved new rules making electronic prescriptions and medication plans compulsory.

The Senate passed the amendments to the Therapeutic Products Act on Thursday in an overwhelming vote of 33 to 1, signaling strong political support for the reform. The primary goal of the change is to improve patient safety and reduce medication errors.

Under the new regulation, healthcare professionals will be required to issue prescriptions exclusively in electronic form. This applies not only to prescriptions but also to medication plans used by patients and medical providers.

Authorities believe that the digital system will reduce the risk of incorrect drug dispensing and improve coordination between doctors, pharmacies, and other healthcare professionals. By enabling better information exchange, the system aims to make treatment more efficient and transparent.

Despite the shift to digital prescriptions, patients will still retain flexibility. Individuals will be able to request a printed copy of their electronic medication plan if needed, ensuring accessibility for those less comfortable with digital tools.

The reform is part of Switzerland’s broader effort to modernize its healthcare infrastructure and integrate digital solutions into everyday medical practice. Officials say this transformation is essential for improving efficiency, safety, and long-term system sustainability.

Health authorities also expect that digital prescriptions will help address challenges such as medicine shortages by improving tracking and coordination across the supply chain.

The new system marks a significant milestone in Switzerland’s healthcare digitalisation strategy and is expected to be implemented across the country in the coming years.

EU Antibiotic Security at Risk, Warns Sandoz.

Swiss-based pharmaceutical company Sandoz has raised serious concerns over the growing import of low-cost antibiotics from China, warning that it could threaten Europe’s healthcare security and industrial stability.

Complaint Filed to European Commission

Sandoz has submitted a draft complaint to the European Commission targeting imports of penicillin-based antibiotics, particularly the active ingredient used in amoxicillin. The company argues that heavily subsidized Chinese production is distorting global competition.

Concerns Over Market Dependency

According to Sandoz CEO Richard Saynor, up to 90% of global antibiotic active substances are now produced outside Europe, mainly in China. He warned that this creates a critical strategic vulnerability for public health systems and crisis preparedness across Europe.

Pricing and Industry Pressure

Sandoz claims that antibiotics are being systematically undervalued in global markets, with pricing structures failing to reflect their importance in healthcare systems. The company argues that this focus on low-cost supply is weakening long-term production sustainability.

Risk to European Production Capacity

The company is actively trying to maintain Europe’s last remaining major antibiotic production facility in Kundl, Austria, which marks its 80th anniversary this year. Industry leaders warn that without stronger protections, Europe risks losing domestic production capability entirely.

Policy Response in Europe

Some progress has been made through initiatives such as the “Alpbach Communiqué,” which proposes that at least 30% of essential medicine supplies should come from European producers.

The EU’s proposed Critical Medicines Act is also seen as a step forward, although implementation details remain uncertain.

Global Comparison and Policy Debate

Sandoz has pointed to India’s policy model, where minimum import pricing is used to protect domestic pharmaceutical production. The company argues that Europe may need similar measures to secure long-term supply stability.

Conclusion

The dispute highlights growing global tensions over pharmaceutical supply chains, pricing fairness, and strategic independence in essential medicines, particularly antibiotics.